Effects of Melatonin-Aided Therapy on the Glutathione Antioxidant System Activity and Liver Protection

Sergey S. Popov, Konstantin K. Shulgin, Tatyana N. Popova, Aleksander N. Pashkov, Aleksander A. Agarkov, and Miguel A. A. Pinheiro de Carvalho

1Department of Endocrinology, Voronezh State Medical Academy, Voronezh, Russian Federation
2Department of Medical Biochemistry and Microbiology, Voronezh State University, Voronezh, Russian Federation
3Department of Biology and Ecology, Voronezh State Medical Academy, Voronezh, Russian Federation
4ISOPlexis Genebank, University of Madeira, Funchal, Portugal; E-mail: quercus@uma.pt
5ICAAM, University of Evora, Portugal

Received 30 December 2014; revised 6 March 2015; accepted 10 March 2015

ABSTRACT: Acute hepatitis results from oxidative stress triggered by hepatotoxic drugs causing liver injury and the activation of caspases cascade. The glutathione antioxidant system protects against reactive oxygen species and mitigates development of these processes. The effectiveness of silymarin, a polyphenolic flavonoid, essenthiale, composed of phosphatidyl choline, and melaxen, a melatonin-correcting drug, as hepatoprotectors has been investigated. The variation of 6-sulfatoxymelatonin (aMT6s), resulting from the biotransformation of melatonin, and GSH has been measured. The activities of caspase-1 and caspase-3, glutathione antioxidant system, and NADPH-generating enzymes were determined. The aMT6s decreases in patients with drug hepatitis and recovers with administration of mexalen. GSH increased in the presence of the studied hepatoprotectors. Pathologically activated caspase-1 and caspase-3 decreased their activities in the presence of hepatoprotectors with melaxen showing the highest effect. The positive effect of melatonin appears to be related to the suppression of decompensation of the glutathione antioxidant system functions, recovery of liver redox status, and the attenuation of inhibition of the NADPH supply.

KEYWORDS: Drug-induced hepatitis; Glutathione antioxidant system; 6-Sulfatoxymelatonin; Reduced glutathione; Hepatoprotectors

INTRODUCTION

Acute hepatitis often occurs as a result of the formation of reactive metabolites in the liver. Hepatotoxic drugs can injure the hepatocyte directly via production of free radical or through metabolite peroxidation of membrane lipids. Reactive oxygen species (ROS) have been implicated in the drug-induced injury. In tuberculosis, inflammatory mediators and oxidative stress may potentiate drugs hepatotoxicity. In these processes, the death ligands, Fas ligand, tumor necrosis factor α (TNF-α), and their cognate receptors can induce liver injury by triggering hepatocyte apoptosis and necrosis [1], activating in the caspases cascade. Caspase-1 and caspase-3 are inflammatory and apoptotic enzymes, signaling ongoing cell damaging processes during hepatitis [2]. Apoptosis may be controlled by the redox status of the hepatocyte [3, 4], constituting a defense mechanism against acute hepatitis [5, 6].

The tissue redox status depends on complex enzymatic mechanisms, whereas the glutathione antioxidant system plays a central role. Glutathione in the reduced (GSH) or oxidized (GSSG) forms, glutathione peroxidase (GPx; EC 1.11.1.9), glutathione reductase (GRx; EC 1.6.4.2), and glutathione S-transferase (GST; EC 2.5.1.18) are involved in the glutathione antioxidant system [7–10]. The system requires supply of NADPH provided by glucose-6-phosphate dehydrogenase (G6PD; EC 1.1.1.49) or NADP–isocitrate dehydrogenase (NADP–IDH; EC 1.1.1.42) [11, 12].

GSH in its reduced form is thought to be the most important intracellular defense against ROS. Its free sulfhydryl group provides an antenna for attack by different oxidative species [7]. GPx uses GSH as
substrate to neutralize hydrogen peroxide and lipid peroxides. Oxidized glutathione (GSSG) is further recycled to its reduced form by GRx using NADPH [8, 9]. One of the major cellular suppliers of NADPH for the glutathione antioxidant system is the pentose phosphate pathway, where G6PD catalyzes transformation of glucose-6-phosphate into 6-phosphogluconolactone with production of NADPH [11]. The needs of the GPx/GRx system for NADPH enhances the disorders disruption of the tissue antioxidative defenses [13]. Alternatively NADPH can be generated by NADP–IDH, which promotes oxidizing decarboxylation of isocitrate into 2-oxoglutarate [12]. Additionally, GST is involved in the antioxidant protection and detoxification of harmful toxic compounds using GSH as a substrate [10], avoiding activation of the reactive oxidative cascade. Therefore, the tissue glutathione antioxidant system has clinical importance.

The glutathione antioxidant system can fail in the defense of liver from injury caused by antituberculosis drugs. In such instance, hepatoprotectors can assist in recovery of the antioxidative status and regenerate damaged tissue. Silymarin, a herbal drug, exhibits hepatoprotective properties due to antioxidant power of the polyphenolic flavonoids [14]. Essenthiale composed of phosphatidyl choline promotes regeneration of cell membranes and suppresses oxidative stress [15]. Melatonin secreted by several body tissues is involved in synchronization of the organism circadian and seasonal biorhythms and present at high concentrations in the mitochondria and cell nucleus, whereas can act as a free radical scavenger [16] effectively protecting membranes, nucleus, and mitochondrial DNA. The possible protective role of melatonin against pathological processes during drug-induced hepatitis is still unknown. Melaxen, a melatonin-regulating drug, could be used to understand its role in liver protection [17]. 6-Sulfatoxymelatonin (aMT6s), major metabolite of melatonin [18], was used to study the hormone metabolism under stress conditions [19].

This work aims to evaluate effectiveness of hepatoprotectors as potential activators of glutathione antioxidant system in the mitigation of inflammatory and apoptotic processes and protection of liver tissue against injuries caused by antituberculosis drugs.

MATERIAL AND METHODS

Study Subject and Sample Groups

A group of 131 individuals, adult man and women were included in the present study (Table 1). Sixty-six individuals with drug-induced hepatitis including 42 man (64%) and 24 woman (36%), age ranging from 18 to 56 years, were used as the experimental groups. All patients who suffered from lungs tuberculosis were treated at the Voronezh regional antitubercular clinics. Diagnoses of a drug-induced hepatitis were made using evaluation of the clinical symptoms, biochemical blood analysis, and an ultrasound exam of the liver. On average, the disease lasted 2.6 ± 0.4 month. The control group was composed of 65 generally healthy people, age ranging from 21 to 52 years, with normal parameters of the general and biochemical blood samples.

Drug-induced hepatitis patients were subdivided into two groups. The first group included 35 patients submitted for 10 days to a standard treatment with hepatoprotectors (silymarine and essenthiale). The second group of 31 individuals received the same standard therapy supplemented with one tablet per day of melaxen (Unifarm, New York, NY, USA) containing 3 mg melatonin. The treatment was administered 30–40 min before bed time for 10 days.

Blood and Urine Samples

Blood serum and urine samples were collected from all individuals twice, at the beginning and end of the study, using standard sampling methods.

Biochemical Parameters Analysis

The BÜHLMANN 6-sulfatoxymelatonin ELISA kit (EK-M6S) was used for the direct and quantitative determination of aMT6s in human urine. The assay used a capture antibody principal based on polyclonal antibody specific for rabbit immunoglobulin coated onto the microtiter plates. The analysis requires 5 μL of urine and has a range sensitivity of 0.8–40 ng/mL. GSH concentration was determined through the reaction with 5,5-dithio-bis-(2-nitrobenzoic) acid [20]. Protein content in blood serum samples was determined according to Lowry [21], using a bovine serum albumin calibration curve.

Measurement of Enzyme Activity

Caspase-1 and caspase-3 activities in blood serum were determined using colorimetric assay kits for caspase-1 and caspase-3 (Sigma-Aldrich Lda, Dorset, UK), respectively. The caspase activity was measured at the 405 nm (molar extinction coefficient = 10.5) as the yield of p-nitroaniline resulting from the hydrolysis of the peptide substrates acetyl-tyr-Val-Ala-Asp-p-nitroanilide (Ac-YVAD-pnA) (for caspase-1)
TABLE 1. Clinical Study Sample Major Features

|                  | Control | Group I | Group II |
|------------------|---------|---------|----------|
| N                | 65      | 66      |          |
| Man              | 42 (64%)| 42 (64%)|          |
| Woman            | 24 (36%)| 24 (36%)|          |
| Ages range (years) | 21–52  | 18–56   |          |
| Mean disease duration (months) | –       | 2.6 ± 0.4|          |
| Groups’ size     | 65      | 35      | 31       |
| Diagnoses        | Yes     | Yes     | Yes      |
| Therapy treatment| None    | Silymarine, essentiale | +Melaxen |

All individuals included in this study have been diagnosed for drug-induced hepatitis or its absence, based on clinical symptoms, biochemical blood analysis, and ultrasound examination. na – not applicable

and acetyl-Asp-Glu-Val-Asp-p-nitroanilide (Ac-DeVD-pnA) (for caspase-3). Caspases specific activity was expressed in picomoles of the product formed during 1 min per 1 mg of the protein.

Activities of other enzymes in blood serum were measured spectrophotometrically at the 340 nm with a Hitachi U-1900 spectrophotometer (Richmond Scientific, Lancashire, UK). Enzyme activity was expressed in catalytic units per 1 mL of serum and the enzyme specific activity as the number of catalytic units per 1 mg of protein. One unit of catalytic activity (U) was defined as the amount of the enzyme activity performing the conversion of 1 μmol of substrate per minute at 25°C. GRx activity was measured in a reagent mixture with 50 mM potassium phosphate buffer (pH 7.4), 1 mM ethylenediaminetetraacetic acid (EDTA), 0.16 mM NADPH, and 0.8 mM oxidized glutathione (GSSG). GPx activity was assayed in the reagent mixture with 50 mM potassium phosphate buffer (pH 7.4), 1 mM EDTA, 0.12 mM NADP, 0.85 mM GSH, 0.37 mM H₂O₂, and 1 U/mL GR. GST activity was determined using 1-chloro 2,4-dinitro benzene (CDNB) [22] in a reagent mixture containing 0.1 M potassium phosphate buffer (pH 6.5), 10 mM GSH, and 1 mM CDNB. G6PD activity was measured in the reagent mixture with 0.05 mM Tris-HCl buffer (pH 7.8), 3.2 mM glucose-6-phosphate, and 0.25 mM NADP. NADP-IDH activity was assayed in 0.05 mm Tris-HCl buffer (pH 7.8) with 1.5 mM isocitrate and 0.25 mM NADP.

All enzymatic reactions have started by the addition of 100 μL of blood serum to the reagent mixtures.

Statistical Analysis

Standard statistical methods were applied to evaluate the obtained data including calculation of mean values, SEM, Student’s t-criterion, and the nonparametric Wilcoxon test using STATISTICA 6.0 software (StatSoft, Tulsa, OK, USA). Differences between the sample parameters and enzyme activities were considered statistically significant at p ≤ 0.05.

Ethical Issues

This study was approved by the Ethical Committee of the Voronezh State Medical Academy governed by the Ministry of Health of Russian Federation. All procedures were carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki of 1975) for experiments involving humans.

Reagents

Chemicals used in this study were of the highest analytical grade available. NADP, NADPH, and GSH were obtained from Sigma. D,L-Isocitrate (trisodium salt) and glucose-6-phosphate were from Sigma Chemical (London, UK), and Tris was supplied by Serva (Germany).

RESULTS

The major features of the subjects included in the present study are shown in Table 1. The drug-induced hepatitis was diagnosed based on a battery of three clinical tests, e.g., clinical observations, biochemical blood analysis, and ultrasound examinations. The candidates suffering from other diseases that could significantly increase the oxidative stress and affect glutathione antioxidant system activity such as viral hepatitis, malignant tumors, acute myocardial infarction, or acute impairment of the cerebral blood stream were excluded from this study.

The activity of caspases in blood serum of all patients with drug-induced hepatitis significantly exceeded the normal values. The specific activity of
caspase-1 and caspase-3 in blood serum was 2.5-fold \( (p < 0.05) \) and 1.7-fold \( (p < 0.05) \) higher, respectively, when compared to the corresponding activities of the control group. The standard therapy decreased the activity of caspase-1 and caspase-3 by 1.6- and 1.1-fold, respectively \( (p < 0.05) \). Additionally, melaxen administration inhibited caspases activity in a more profound way, which was, respectively, 2.2- and 1.6-fold lower when compared to the values before the onset of therapy \( p < 0.05 \) (Figure 1). These results indicate that inflammatory and apoptotic processes undergoing during the drug-induced hepatitis are accompanied by an increase in the caspases’ activity that seem to be effectively inhibited by the hepatoprotectors particularly in the presence of melaxen.

Quantification of the aMT6s level in urine revealed a difference between the control group \((8.99 \text{ ng} \cdot \text{mL}^{-1})\) and the patients \((6.21 \text{ ng} \cdot \text{mL}^{-1})\) before the treatment (Figure 2). The standard and aided melaxen therapies allowed the recovery of aMT6s levels at 11.7% and to control \((9.12 \text{ ng} \cdot \text{mL}^{-1})\) levels, respectively. The results between control and experimental groups before the therapy and between the onset and the final therapy with melaxen are statistically different, suggesting that melaxen enhances melatonin levels in the patient’s blood and thus protects the liver.

Changes in the content of GSH blood serum in the control and experimental groups before and after 10 days of therapy indicate that consumption of reduced glutathione increases in patients with drug-induced hepatitis (Figure 2). The GSH content was two fold lower compared to the control group. Lower content of GSH could be associated with a significantly increased demand for this metabolite during the intensification of free radical oxidation. The treatment with the hepatoprotectors allows a recovery of 56.8% of glutathione redox level in the standard therapy and return to the levels of control group in the patients under the therapy aided by melaxen. This increase correlates with changes in aMT6s and is clearly connected with the protective effect of melatonin and its positive action on the tissue glutathione redox status.

The fluctuations in the catalytic and specific activities of glutathione antioxidant system enzymes (GPx, GRx, and GST) in the control and experimental groups before and after 10 days therapy have been analyzed. An enhancement of GPx and GRx activities and a decrease in GST were observed in patients with drug-induced hepatitis when compared to the control group. GPx and GRx activities in the patients groups before the therapy were 1.3- and 2.2-fold \( (p < 0.05) \) higher than the control group. The enzymes specific activity exhibited the same trend with the increase in 1.1- and 1.4-fold \( (p < 0.05) \). This initial stimulation of the GPx/GRx system could be due to its induction to counteract the effect of uncontrolled ROS production and oxidative stress during the pathology development. Oxidative stress simultaneously enhanced the apoptotic processes, which was reflected by the increase in the caspases activity. Administration of the hepatoprotectors through standard therapy promoted the activation of GPx and GRx 1.2-fold \( (p < 0.05) \) and 1.1-fold, respectively, when compared to the onset of the treatment. This enhancement was accompanied by gains in the GPx and GRx specific activities, which rose 18.5% \( (p < 0.05) \) and 5.3%, respectively. The GPx and GRx activities also exceeded normal values in the patients’ blood of the second group. However its variation range is larger, when the enzymes activity before the onset and the end of therapy was compared (Figure 3). Thus, therapy aided by melaxen resulted in a stronger GPx and GRx activation, with an increase in the catalytic activity by 2.1- and 1.8-fold and...
specific catalytic activity by 1.4- and 1.5-fold, respectively ($p < 0.05$). The enhancement of GPx and GRx specific activities could indicate a possible induction of enzymatic expression in the presence of melaxen.

The decrease in GST activity in blood serum (Figure 4) was 1.6-fold ($p < 0.05$) lower, while its specific activity was 1.7-fold lower in comparison with the control group. The decrease in GST activity may be associated with competition for GSH when its turnover through the GPx/GRx system increases to prevent oxidative damage caused by ROS to the cellular and tissue structures. Standard therapy increased GST activity and specific activity by 1.5-fold ($p < 0.05$) and 1.4-fold, respectively, in comparison with the onset of
the therapy. This increase could be perhaps connected
with the enhancement of the GSH cellular pool as
a result of the hepatoprotectors action, which allows
GST to participate in the protective mechanism directly
neutralizing drug toxins. Similarly, the GST activity and
specific activity in the patients of the second group
has also increased by 1.8-fold ($p < 0.05$) and 1.7-fold
($p < 0.05$), respectively, after the therapy aided by
melaxen. These data are consistent with the availability
of high cellular GSH concentration (Figure 2) promoted
by the GRx (Figure 3), which is the primary substrate
of GST acting as an acceptor of the antituberculosis
drugs. Perhaps a certain predetermined level of GSH is
needed to raise GST activity, which in turn could occur
through the enzyme induction under oxidative stress.

The activity of glutathione antioxidant system and
regeneration of GSH under oxidative stress require a
constant supply of NADPH as reduction power, which
could be supported by the work of G6PD or NADP–
IDH. However, a decrease in the G6PD activity and
specific activity of 1.5-fold ($p < 0.05$) and 1.4-fold,
respectively, was observed in blood samples of the
patients when compared to the control group (Figure 5).
G6PD is a main supplier of NADPH for GSH regeneration
by GRx and the decrease in its activity is consistent
with GSH lowest levels and decrease in GST activity.
At the same time, the catalytic activity and the specific
activity of NADP–IDH in the blood serum of patients
groups before the therapy was 1.3- and 1.1-fold lower
than in the control group. NADP–IDH is an alternative
supplier of NADPH for GSH regeneration by GRx and
its inhibition is consistent with the observed decrease
in GSH levels and GST activity during drug-induced
hepatitis.

After the standard therapy, the activity of G6PD
and NADP–IDH increased by 25.3% and 10.6%, re-
spectively. Similarly, G6PD and NADP–IDH specific
activities raised by 1.3- and 1.1-fold, respectively
(Figure 5). This difference was evidently related to
the positive effect of the hepatoprotectors on the
hepatocytes metabolism and could be coupled with
activation of glutathione antioxidant system and GTS
(conjugation function) observed after the treatment
with carsil and/or essenthiale. The therapy aided by
melaxen showed to be even more effective and resulted
in the 1.7- and 1.2-fold increase in G6PD and NADP–
IDH activities. At the same time, G6PD and NADP–
IDH specific activities increased by 1.5-fold ($p < 0.05$)
and 1.2-fold. Activation of the NADPH-generating en-
zymes was higher when the standard treatment was
combined with melaxen. This activation resulted in
a significant increase in all enzymatic activities (GRx,
GPx, and GST) of the glutathione antioxidant system
(Figures 3 and 4).

Comprehensive analysis of these data indicates
that melatonin can play a role of an adaptogene capable
to promote a regulatory action on free radical home-
ostasis and apoptosis processes, positively influencing
the ROS scavenging potential of tissue through the acti-
vation of glutathione antioxidant system supported by
the NADP-supplying enzymes during oxidative stress
caused by drugs during hepatitis.

**DISCUSSION**

In the liver, cytochrome P450 is the defense against
cells damage performing drugs bioinactivation. Neu-
tralization of xenobiotics additionally leads to the ROS
production, inducing the oxidative stress. Oxidative
conditions can stimulate Fas ligand synthesis enhanc-
ing hepatocytes susceptibility to apoptosis [23]. The Fas
FIGURE 5. Variation of glucose-6-phosphate dehydrogenase (G6PD; EC 1.1.1.49) (1) and NADP-dependent isocitrate dehydrogenase (NADP-IDH; EC 1.1.1.42) (2) catalytic activity expressed in U/mL (A) and specific catalytic activity expressed in U/mg protein (B) in blood serum of control group (1), in patients with drug-induced hepatitis, at the beginning (first column) and after 10 days (second column) of traditional therapy administration (2), and traditional therapy combined with melaxen (3): before (first column) and after (second column) therapy.

L is exceeded in acute liver failure as a result of its expression [24] and is suggested to activate the caspases. The enhancement of caspases activity is associated with the oxidative stress and Fas-mediated apoptotic processes. The increase in the caspases activity during Fas-induced apoptosis [24] results from sequential activation of caspase-1- and caspase-3-like proteases [25] and can be suppressed by enzyme inhibitors [24]. The decrease in caspases activity was also associated with hepatoprotectors, where melaxen demonstrated the stronger effect. Melatonin positively inhibits the apoptotic processes by enhancing the expression of antiapoptotic Bcl-2 genes [26, 27]. Melaxen intake corrects melatonin levels, attenuating free radical oxidation and inhibiting inflammatory and apoptotic processes.

The role of melatonin in ROS neutralization can be estimated based on aMT6s changes [19, 28], in which reduction is associated with melatonin use as a ROS scavenger, reactivating peroxyl radicals [29], singlet oxygen species [30], and hydrogen peroxide with the formation of 3-hydroxymelatonin [31]. Melatonin metabolites including aMT6s can themselves detoxify radicals [32, 33]. These events are named “antioxidant cascade of melatonin” [33, 34]. The aMT6s variation in the presence of hepatoprotectors shows an increase in liver protection by this cascade.

The GSH variation is consistent with its direct use in ROS scavenging [35] or indirectly in enzymatic processes, providing tissues antioxidant defense [7]. Carsil and essenthiale promote the GSH increase, decreasing ROS activity. Higher GSH in the presence of melaxen can be explained by melatonin synergistic action on ROS scavenging and glutathione antioxidant system activity. Enhanced glutathione antioxidant system oxidation and reduction functions are a response to ROS activity. GPx is induced by oxidative stress [36], increasing the needs for GSH not sufficiently compensated by the GRx. The positive effect of hepatoprotectors results in an overall increase in GAS, including conjugation (GST) function. Melatonin promotes the NADPH-dependent GSSG reduction by GRx [37], surpassing the needs for GSH [38], which is consistent with higher GRx activity in the presence of melaxen. The increase in GSH and aMT6s support these observations.
and indicate that melatonin activity can be connected with the expression of antioxidant enzymes [16]. The decrease in GST activity may be associated with competition of the GPx/GRx system for GSH. GST is a key enzyme in drugs detoxification through conjugation [39], removing them from the blood [10] and avoiding the beginning of stress cascade.

G6PD activity decrease is consistent with gluconeogenesis hampering and glycolysis enhancement in the injured liver [40], with the suppression of the anaplerotic branchpoint of pentose phosphate pathway. Suppression of the oxidative metabolism during liver intoxication is connected with metabolic disorders in hypoxic conditions [40]. Glutathione antioxidant system mobilization can be limited also by the NADP–IDH inhibition affecting the NADPH supply [41] and GST [39]. The inhibition of NADPH supplying enzymes might be the main causes of GSH decrease. The distinguished effects of the hepatoprotectors with more effective action of melaxen on the glutathione antioxidant system activity are consistent with this system induction after exposure to melatonin [42].

CONCLUSIONS

Our study demonstrated that drug-induced hepatitis is accompanied by a decrease in aMT6s and GSH levels, enhancement of caspase-1 and caspase-3 activity, and disturbances of the glutathione antioxidant system activity. The reduction of aMT6s and GSH at pathology is explained by the dilapidation of melatonin and GSH in ROS neutralization. The increase in caspase-1 and caspase-3 activities is an indicator of undergoing inflammatory and apoptotic processes mediated by the Fas receptor. The decrease in GSH content and the GST activity reflects the disturbance of glutathione antioxidant system functioning under oxidative stress that is not compensated by the increase in GRx and GPx activity. Therapy with the hepatoprotectors aided with melaxen seems to be effective to compensate the disorders in the function of enzyme and nonenzyme components of the glutathione antioxidant system. It can be concluded that correction of tissue oxidant–antioxidant status is an important part of the effective therapy against drug-induced hepatitis.

ACKNOWLEDGMENT

This work was supported by grant of the President of the Russian Federation for young scientists MK-3133.2011.7. Authors thank to President of Voronezh State Medical Academy named after N. N. Burdenko (Russia), Prof. Igor E. Esaulenko, for advice and suggestions.

REFERENCES

1. Montgomery Bissell D, Gores GJ, Laskin DL, Hoofnagle JH. Drug-induced liver injury: mechanisms and test systems. Hepatology 2001;33(4):1009–1013.
2. McIlwain DR, Berger Th, Mak TK. Caspase functions in cell death and disease. Cold Spring Harb Perspect Biol 2013;5(a008656):1–29.
3. Hentze H, Gantner F, Kolb SA, Wendel A. Depletion of hepatic glutathione prevents death receptor-dependent apoptotic and necrotic liver injury in mice. Am J Pathol 2000;156:2045–2056.
4. Latta M, Kunstle G, Leist M, Wendel A. Metabolic depletion of ATP by fructose inversely controls CD 95- and tumor necrosis factor receptor 1-mediated hepatic apoptosis. J Exp Med 2000;191:1975–1985.
5. Lukaszewicz-Hussain A, Moniuszko-Jakoniuk J. Liver catalase, glutathione peroxidase and reductase activity, reduced glutathione and hydrogen peroxide levels in acute intoxication with chlorfenvinphos, an organophosphate insecticide. Polish J Environ Stud 2004;13(3):303–309.
6. Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 1996;9:2026–2030.
7. Szalai G, Kellos T, Galiba G, Kocsy G. Glutathione as an antioxidant and regulatory molecule in plants under abiotic stress conditions. J Plant Growth Regul 2009;28:66–80.
8. Eshdat Y, Holland D, Faltin Z, Benhayyim G. Plant glutathione peroxidases. Physiol Plant 1997;100:234–240.
9. Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M, Nguyen AT, Thévenin M, Jaudon MCh, Zingraff J, Verger Ch, Jungers P, Descamps-Latscha B. Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med 1996;21(6):845–853.
10. Smith GJ, Ohl VS, Ligandin LG. The glutathione S-transferases, and chemically induced hepato carcinogenesis. A review. Cancer Res 1977;37:8–14.
11. Ramnanan ChJ, Storey KB. Glucose-6-phosphate dehydrogenase regulation during hypometabolism. Biochem Biophys Res Comm 2006;339:7–16.
12. Medvedeva LV, Popova TN, Artiukov VG, Matasova LV, Pinheiro de Carvalho MA. Intensity of free radical processes and regulation of cytoplasmic NADP-isocitrate dehydrogenase in rat cardiomyocytes under normal and ischemic conditions. Biochemistry (Moscow) 2002;67(6):696–705.
13. Luzzato L, Metha A, Vulliamy T. Glucose 6-phosphate dehydrogenase deficiency. In: Scrivener CR, Beaudet AL, Sly WS, editors. The metabolic and molecular bases of inherited disease, 8th edition. Columbus, OH: McGraw-Hill: 2001. pp 4517–4553.
14. Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res 2006;124:491–504.
15. Aleynik AI, Leo MA, Aleynik MK, Lieber CS. Polyenylphosphatidylcholine protects against alcohol
but not iron-induced oxidative stress in the liver. Alcohol Clin Exp Res 2000;24:196–206.

16. Reiter RJ, Tan D, Mayo JC, Sainz RM, Leon J, Czarnocki Z. Melatonin as an antioxidant: biochemical mechanisms and pathophysiological implications in humans. Acta Biochim Pol 2003;50(4):1129–1146.

17. Oshima T, Pavlick KP, Laroux FS, Verma SK, Jordan P, Grisham MB, Williams L, Alexander JS. Regulation and distribution of MAdCAM-1 in endothelial cells in vitro. Am J Physiol Cell Physiol 2001,281:C1096–C1105.

18. Bespalykh AY, Brodsky VYa, Burlakova OV, Golichenkov V, Voznesenskaya LA, Kolesnikov DB, Molchanov AY, Rapoport SI. Melatonin: theory and practice. Moscow, Russia: Medical practice; 2009.

19. Arendt J. Melatonin and the mammalian pineal gland. London, UK: Chapman & Hall; 1995.

20. Arutyunyan AV, Dubinin EE, Zybina NN. Methods of estimation of free radical oxidation and antioxidant system of an organism. St. Petersburg, Russia: IKF Foliant; 2000.

21. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin-phenol reagent. J Biol Chem 1951;193:265–275.

22. Warholm M, Guthenberg C, von Bahr Ch, Mannervik B. Glutathione transferases from human liver. In: Melster A, editor. Methods of enzymology. New York: Academic Press; 1985. Vol 113, pp 500–501.

23. Soderman T, Bronk SF, Roberts PJ, Miyoshi H, Gores GJ. Bile salts mediate hepaticocyte apoptosis by increasing cell surface trafficking of Fas. Am J Physiol Gastrointest Liver Physiol 2000;279:992–999.

24. Rutherford AE, Hyman LS, Borges CB, Forcione DG, Blackard JT, Lin W, Gorman AR, Obaid SS, Reuben A, Harrison E, Reddy KR, Le WM, Chung RT, and for the ALF Study Group. Serum apoptosis markers in acute liver failure: a pilot study. Clin Gastroenterol Hepatol 2007;5:1477–1483.

25. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Iton N, Suda T, Nagata S. Lethal effect of the anti-Fas antibody in mice. Nature 1993;364(6440):806–809.

26. Guha M, Maity P, Choubey V, Mitra K, Reiter RJ, Bandopadhyay U. Melatonin inhibits free radical-mediated mitochondrial dependent hepatocyte apoptosis and liver damage induced during malarial infection. J Pineal Res 2007;43:72–81.

27. Baydas G, Koz ST, Tuzcu M, Etem E, Nedzvetsky VS. Melatonin inhibits oxidative stress and apoptosis in fetal brains of hyperhomocysteinemic rat dams. J Pineal Res 2007;43:225–231.

28. Mathes AM. Hepatoprotective actions of melatonin: possible mediation by melatonin receptors. World J Gastroenterol 2010;16(48):4608–4609.

29. Pieri C, Marra M, Moroni F, Recchioni R, Marcheselli F. Melatonin: a peroxyl radical scavenger more effective than vitamin. E Life Sci 1994;55:PL271–PL276.

30. Cagnoli CM, Atabay C, Kharlamova E, Manev H. Melatonin protects neurons from singlet oxygen-induced apoptosis. J Pineal Res 1995;18:222–226.

31. Tan DX, Manchester LC, Reiter RJ, Plummer BF, Hardies LJ, Weintraub ST, Vijayalaxmi Shepherd AM. A novel melatonin metabolite, cyclic 3-hydroxymelatonin: a biomarker of in vivo hydroxyl radical generation. Biochem Biophys Res Commun 1998;253:614–620.

32. Guenther AL, Schmidt SI, Laatsch H, Fots S, Ness H, Ressmeyer AR, Poeggeler B, Hardeland R. Reactions of the melatonin metabolite AMK (N1-acetyl-5-methoxynuramine) with reactive nitrogen species: formation of novel compounds, 3-acetamidomethyl-6-methoxyacinolinolone and 3-nitro-AMK. J Pineal Res 2005;39:251–260.

33. Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res 2007;42:8–42.

34. Reiter RJ, Tan DJ, Manchester LC, Pilar Terron M, Flores LJ, Koppiwepi S. Medical implications of melatonin: receptor-mediated and receptor-independent actions. Adv Med Sci 2007;52:11–28.

35. Smirnova GV, Oktyabrsyk ON. Glutathione in bacteria. Biochemistry 2005;70(11):1199–1211.

36. Chandra R, Anea R, Rewal C, Konduri R, Dass K, Aragwal S. An opium alkaloid-papaverine ameliorates ethanol induced hepatotoxicity: diminution of oxidative stress. Indian J Clin Biochem 2000;15(2):155–160.

37. Baets E, Fernandez-Tresguerres J, Ariznavarreta C, De La Fuente M. Effects of growth hormone, melatonin, oestrogens and phytoestrogens on the oxidized glutathione (GSSG)/reduced glutathione (GSH) ratio and lipid peroxidation in aged ovariectomized rats. Biogerontology 2010;11:687–701.

38. Agapito MT, Redondo I, Plaza R, Lopez-Burillo S, Recio JM, Pablos MI. Relationships between melatonin, glutathione peroxidase, glutathione reductase, and catalase. Endogenous rhythms on cerebral cortex in Gallus domesticus. Adv Exp Med Biol 1999;460:377–381.

39. Eaton DL, Bammler TK. Concise review of the glutathione S-transferase and their significance to toxicity. Toxicol Sci 1999;49:156–164.

40. Berezov TT. Biological chemistry. Moscow, Russia: Medicine; 2008.

41. Popova N, Pashkov NA, Semenihina AV, Popov SS, Rakhmanova TI. Free radical processes in the biological systems. St. Oskol, Russia: IPK Kirillica; 2008.

42. Iskusnykh IY, Popova TN, Agarkov AA,Pinheiro de Carvalho MAA, Kvesik SG. Expression of glutathione peroxidase and glutathione reductase and level of free radical processes under toxic hepatitis in rats. J Toxicol 2013;160. DOI 10.1155/2013/870628.